So another test for ovarian cancer?
Sub-B2M prototype achieved 100% sensitivity and specificity. So does Bard1 anticipate this new exosome-based test to be obsolete before reaching the market?
Ann: BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data, page-12
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.5¢ |
Change
0.020(3.54%) |
Mkt cap ! $64.51M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 60.5¢ | 57.0¢ | $30.40K | 51.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 290 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |